4DMedical

4DMedical progresses to a commercial agreement with Qscan

Respiratory imaging technology company 4DMedical Limited (ASX:4DX, “4DMedical”, or the “Company”) today announces the signing of a commercial contract with Qscan Radiology Clinics ("Qscan"), a leading provider of diagnostic imaging services in Queensland. This agreement follows a successful pilot of 4DMedical’s products with Qscan, and represents the first Australian contract to incorporate products from both the Pulmonary Function and Pulmonary Structure suites, including CT LVAS™.


Pilot success leads to commercial agreement

With 40 clinics across Queensland, New South Wales, ACT, Tasmania, and Western Australia, Qscan is one of Australia’s leading medical imaging providers, offering a comprehensive range of diagnostic and interventional radiology services.

Following the success of a pilot program, which demonstrated the clinical and operational effectiveness of 4DMedical’s proprietary suite of products, 4DMedical and Qscan have entered a commercial arrangement under which Qscan will offer 4DMedical’s respiratory imaging solutions at select practices in Brisbane.

This agreement marks 4DMedical’s first Australian commercial contract to incorporate products from both its Pulmonary Function and Pulmonary Structure suites. Specifically, the agreement with Qscan will provide clinicians with access to CT LVAS™, Lung Density Analysis™ - Inspiration (LDAi), Functional Lung Density Analysis™ (LDAf), and Lung Texture Analysis™ (LTA), each providing advanced diagnostic capabilities to support referrers and patients.

Reports will be delivered and billed on a Software-as-a-Service model on terms in line with those of the Company’s other commercial partners.

4DMedical MD/CEO and Founder Andreas Fouras said:

Having completed our pilot with Qscan, we are excited to have progressed to a commercial agreement. This partnership ensures that more patients and clinicians have access to detailed, actionable insights into lung health, supporting better healthcare outcomes.

Momentum continues to build with the commercialisation of our technology across the US and Australia. With the addition of Qscan to our network of providers in Australia, I am excited to see our footprint expand to ensure our cutting-edge technology is now becoming more readily available to all Australians.


Click here for the full ASX Release

This article includes content from 4DMedical, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

The Conversation (0)
Tech 5: OpenAI Restructures, Apple Pursues AI Search, Constellation Shares Jump

Tech 5: OpenAI Restructures, Apple Pursues AI Search, Constellation Shares Jump

This week proved pivotal for the tech and energy sectors as market dynamics and the regulatory landscape shifted.

Apple (NASDAQ:AAPL) made waves by signaling a foray into artificial intelligence (AI) search and challenging app store regulations, while OpenAI underwent a major restructuring amid legal battles with Elon Musk.

Meanwhile, legislation targeting AI chip tracking gained momentum, and the nuclear energy sector saw increased activity with Ontario Power Generation's new reactor project and potential White House actions.

Keep reading...Show less
RemSense Technologies

RemSense Technologies

Keep reading...Show less
Robotic hand and human hand reaching out to touch glowing brain.

ASX AI Stocks: 5 Biggest Companies in 2025

Artificial intelligence (AI) continues to evolve and advance rapidly, becoming increasingly integrated in the automation of everyday life and a focal point of growth in the technology sector.

According to a September 2023 report from IDC on worldwide AI spending, Australia, along with Korea and India, is leading the Asia-Pacific region in spending on AI solutions; the three countries are also leading when it comes to AI adoption in the area. Spending in the region, excluding Japan and China, is expected to reach US$28.2 billion by 2027.

Although the AI market is relatively small in Australia, it’s growing. To help investors understand the options available, the Investing News Network used TradingView's stock screener to find the top AI stocks on ASX by market cap. All ASX AI stocks data was current as of April 7, 2025. companies whose businesses are focused mainly on AI were considered.

Keep reading...Show less
Hands holding a glowing AI circuit with digital network icons.

AI Market Update: Q1 2025 in Review

The first quarter of 2025 was dynamic and often volatile for the tech sector. Initial optimism, fueled by investor enthusiasm after a strong 2024, quickly gave way to economic headwinds and market anxieties.

Concerns over monetary policy, global trade tensions and individual company performances led to variations in tech stock valuations, with the Magnificent Seven ultimately experiencing losses by March.

However, Q1 also brought groundbreaking developments in artificial intelligence (AI), intense competition in the semiconductor industry and new developments in AI agents and robotics.

Keep reading...Show less

Latest Press Releases

Related News

×